Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.
We describe the use of pretargeted radioimmunotherapy (PRIT) using an anti-murine CD45 antibody-streptavidin (SA) conjugate followed by radiobiotin to deliver radiation selectively to murine hematolymphoid tissues, which may potentially augment the efficacy and decrease the toxicity of radioimmunotherapy for disseminated murine leukemia. Biodistribution and therapeutic results demonstrated high target organ to nontarget organ ratios of radioactivity and significant long-term survival in leukemic mice using PRIT. These data suggest that anti-CD45 PRIT using an anti-CD45-SA conjugate in a syngeneic murine model of disseminated leukemia may be more effective and less toxic than directly labeled monoclonal antibodies.
Pagel
John M
JM
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. jpagel@fhcrc.org
Hedin
Nathan
N
Drouet
Lacey
L
Wood
Brent L
BL
Pantelias
Anastasia
A
Lin
Yukang
Y
Hamlin
Donald K
DK
Wilbur
D Scott
DS
Gopal
Ajay K
AK
Green
Damian
D
Appelbaum
Frederick R
FR
Press
Oliver W
OW
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000473:pathology / Q000532:radiotherapy*; D017493:Leukocyte Common Antigens / Q000276:immunology*; D051379:Mice; D008815:Mice, Inbred Strains; D016499:Radioimmunotherapy / Q000379:methods*
D007457:Iodine Radioisotopes; D017493:Leukocyte Common Antigens